Global Pharma’s Formulations Facility Achieves EU GMP Certification for the Second Time
Chennai, India — In a significant reaffirmation of its global quality standards, Global Pharma has once again earned the prestigious EU Good Manufacturing Practice (EU GMP) certification for its formulations manufacturing facility in Chennai, India. This marks the second EU GMP approval for the site, further solidifying the company’s position as a trusted pharmaceutical manufacturer for international markets.
A Testament to Quality and Commitment
For over two decades, Global Pharma has been dedicated to ensuring the health and well-being of communities across the globe. Its formulations unit—established more than 30 years ago in Chennai—has been a cornerstone of its global operations, supplying a wide range of pharmaceutical products across therapeutic areas to markets in Southeast Asia, Central America, LATAM, CIS countries, Africa, Europe, and the United Kingdom.
The repeat EU GMP approval underscores Global Pharma’s consistent adherence to the highest international regulatory standards. It reflects the facility’s robust systems in quality control, production practices, compliance, and documentation—essentials for supplying medicines to regulated markets within the European Union and beyond.
Global Reach Backed by Local Strength
With manufacturing operations in India and Ethiopia, Global Pharma has built an agile, integrated supply chain that supports global distribution. Its formulations are now trusted by healthcare providers across more than 40 countries, earning a reputation for reliability, efficacy, and affordability.
This milestone further enhances the company’s ability to expand into new regulated markets and reinforces trust with existing partners and distributors.
A Vision-Driven Organization
Much of the company’s growth and reputation is credited to the vision and leadership of Dr. Venkatesh, Founder and Managing Director of Global Pharma. Since inception, he has remained committed to building a company that stands for quality, innovation, ethical business practices, and exceptional customer service.
Chennai, India — In a significant reaffirmation of its global quality standards, Global Pharma has once again earned the prestigious EU Good Manufacturing Practice (EU GMP) certification for its formulations manufacturing facility in Chennai, India. This marks the second EU GMP approval for the site, further solidifying the company’s position as a trusted pharmaceutical manufacturer for international markets.
A Testament to Quality and Commitment
For over two decades, Global Pharma has been dedicated to ensuring the health and well-being of communities across the globe. Its formulations unit—established more than 30 years ago in Chennai—has been a cornerstone of its global operations, supplying a wide range of pharmaceutical products across therapeutic areas to markets in Southeast Asia, Central America, LATAM, CIS countries, Africa, Europe, and the United Kingdom.
The repeat EU GMP approval underscores Global Pharma’s consistent adherence to the highest international regulatory standards. It reflects the facility’s robust systems in quality control, production practices, compliance, and documentation—essentials for supplying medicines to regulated markets within the European Union and beyond.
Global Reach Backed by Local Strength
With manufacturing operations in India and Ethiopia, Global Pharma has built an agile, integrated supply chain that supports global distribution. Its formulations are now trusted by healthcare providers across more than 40 countries, earning a reputation for reliability, efficacy, and affordability.
This milestone further enhances the company’s ability to expand into new regulated markets and reinforces trust with existing partners and distributors.
A Vision-Driven Organization
Much of the company’s growth and reputation is credited to the vision and leadership of Dr. Venkatesh, Founder and Managing Director of Global Pharma. Since inception, he has remained committed to building a company that stands for quality, innovation, ethical business practices, and exceptional customer service.
Additional eye drops recalled by FDA
24 June 2024
Contaminated Eye Drop Products
26 June 2024
